leadXpro and Alipheron combine technologies for innovative early drug discovery

leadXpro, specialized in modern structure-based lead discovery in membrane proteins, and Alipheron AG, a provider of innovative software solutions for drug discovery informatics, are pleased to announce a strategic collaboration aimed at accelerating the drug discovery process.

This partnership combines leadXpro's extensive expertise in structural biology with Alipheron's innovative software suite for virtual screening of ultra large combinatorial libraries.

«We are excited to partner with Alipheron, whose state-of-the-art informatics solutions will significantly complement our modern lead discovery approach," said Luboš Remeň, Director of Lead Medicinal Chemistry at leadXpro. "This collaboration will allow us to leverage our strengths in structural biology and virtual screening, ultimately speeding up the discovery of new molecules and accelerate the development of new and effective therapeutics.»

«Partnering with leadXpro aligns perfectly with our mission to provide superior software that drives scientific innovation," said Modest von Korff, CEO of Alipheron. "Our software platform, which includes 3D pharmacophore screening, substructure search, and high-throughput docking of ultra-large combinatorial libraries containing trillions of molecules, will be combined with leadXpro's structural biology and lead discovery capabilities.»

The goal of the collaboration is to develop a protein-structure-driven virtual screening approach on ultra-large combinatorial libraries as an alternative to classical high-throughput screening (HTS) in drug discovery. This groundbreaking approach represents a significant step forward in the shared goal of both companies to improve human health through innovative drug discovery.